The main effect of Recombinant Human Cerebral Natriuretic Peptide for Injection is to regulate blood volume, blood pressure and water-salt balance, and can also increase vascular permeability, reduce vascular resistance and plasma volume in the body circulation, increase cardiac output and reduce cardiac load. It is recommended to consult a specialist and use the medication according to the doctor’s instructions. Recombinant human brain natriuretic peptide for injection can increase glomerular filtration rate, promote sodium excretion, reduce renin and aldosterone secretion, and also inhibit posterior lobe pressor and sympathetic part of the effect of sodium excretion and drainage, and reduce blood pressure. It is suitable for the intravenous treatment of patients with acute decompensated heart failure of NYHA classification greater than class II, i.e., dyspnea at rest or with light activity. The drug is administered clinically by continuous intravenous infusion for 24 hours, with dosage adjusted according to blood pressure. Adverse reactions include hypotension, headache, nausea, and elevated blood creatinine. It is contraindicated in patients who are hypersensitive to any of the components of the drug and in patients with cardiogenic shock or systolic blood pressure < 90 mmHg. Certain special groups, such as pregnant and lactating women, children, etc., are recommended to use the drug strictly in accordance with medical advice to avoid adverse effects.